RELATED STORY: David Tuveson: Decoding a Cryptic Cancer
In addition to holding positions at Cold Spring Harbor Laboratory, David Tuveson is the Director of Research for the Lustgarten Pancreatic Cancer Research Foundation, and he cares for pancreatic cancer patients at Memorial Sloan Kettering Cancer Center. He received his medical and graduate training at the Johns Hopkins University School of Medicine, followed by clinical training at Brigham and Women’s Hospital and Dana-Farber/Harvard Cancer Center. While at Dana-Farber,Tuveson codeveloped imatinib with George Demetri for gastrointestinal stromal tumor patients. Following postdoctoral training with Tyler Jacks at MIT, Tuveson directed laboratories at the University of Pennsylvania and the University of Cambridge prior to moving to Cold Spring Harbor in 2012.
His research team established mouse models of pancreatic cancer to explore the biology of the disease and identify new therapeutic and diagnostic approaches. They created several therapeutic opportunities regarding stromal targeting that are now undergoing clinical evaluation. Most recently, they developed murine and human organoid models of pancreatic cancer to expedite fundamental and applied research.